10-K: Akari Therapeutics Focuses on Oncology Pipeline After Merger, Outlines Financial Risks in 10-K Filing

Sentiment:

Annual Results 15 April 2025 4:33 PM

Akari Therapeutics shifts focus to oncology with its ADC platform following a merger, while acknowledging significant financial risks and material weaknesses in internal controls in its recent 10-K filing.

Delay expectedThe document mentions potential delays in the commencement, enrollment, or completion of clinical trials.

Capital raiseThe company states that it will require substantial additional capital to fund its operations.The company may seek additional funding through future debt and equity financing, potential collaborations or strategic partnerships with other companies, non-dilutive financings or the divestiture of programs and product candidates that it has ceased developing or may in the future cease developing.The company has no committed source of additional capital.

Worse than expectedThe company's net losses increased from $10.0 million in 2023 to $19.8 million in 2024.The company's accumulated deficit increased from $227.5 million in 2023 to $247.3 million in 2024.The company identified material weaknesses in its internal control over financial reporting.

Summary

Akari Therapeutics is now primarily focused on developing next-generation antibody-drug conjugates (ADCs) for cancer therapy.
The company's lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC for solid tumors.
Akari aims to establish AKTX-101 as a best-in-class Trop2-targeting ADC.
Following a merger with Peak Bio, Akari suspended internal development of legacy programs and seeks strategic partners.
The company faces significant financial risks, including a history of operating losses and the need for substantial additional capital.
As of December 31, 2024, Akari had approximately $2.6 million in cash.
The company acknowledges material weaknesses in its internal control over financial reporting.
The company incurred net losses of $19.8 million and $10.0 million for the years ended December 31, 2024 and 2023, respectively.
The company's accumulated deficit as of December 31, 2024 was $247.3 million.
The company has cumulative UK, U.S. federal, various U.S. state, Switzerland, and South Korea net operating loss carryforwards (NOL) to offset future taxable income of approximately $145.7 million, $38.1 million, $71.8 million, less than $0.3 million, and $87.0 million, respectively.
The company aims to create more effective and safer ADC cancer therapies by leveraging its novel payload expertise to potentially improve cancer outcomes for patients.
In March 2025, Abizer Gaslightwala was appointed as President and CEO, effective April 21, 2025.
The company is also pursuing research on two additional novel payloads that possess distinct MoAs from those demonstrated by traditional payloads: PH5 and PH6.
The company is also subject to the U.S. Foreign Corrupt Practices Act (FCPA), the U.K. Bribery Act (Bribery Act), and other anticorruption laws and regulations pertaining to our financial relationships with foreign government officials.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is focusing on a promising area of cancer therapy and has a new CEO, it faces significant financial challenges and has identified material weaknesses in its internal control. The company's future success is highly dependent on its ability to raise additional capital and successfully develop and commercialize its product candidates.

Positives

The company is focusing on a promising area of cancer therapy with its ADC platform.
The company has a new CEO with a proven track record in oncology therapy development.
The company has a significant amount of net operating loss carryforwards to offset future taxable income.
The company is actively seeking partnerships to advance its legacy programs.

Negatives

The company has a history of operating losses and a substantial accumulated deficit.
The company needs to raise substantial additional capital to fund its operations.
The company has identified material weaknesses in its internal control over financial reporting.
The company has not initiated clinical studies for any of the programs in its active pipeline.
The company has suspended internal development of its legacy programs.

Risks

The company may be unable to obtain additional capital when needed.
Preclinical studies or clinical trials of product candidates may be prolonged or delayed.
The company may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities.
The company's industry is highly competitive, and its product candidates may become obsolete.
The company may fail to achieve market acceptance by physicians, patients, and third-party payors.
The company's future growth may depend on its ability to commercialize products in foreign markets, where it would be subject to additional regulatory burdens and other risks and uncertainties.
The company may fail to meet the requirements for continued listing on Nasdaq, causing its ADSs to be delisted.
The company is subject to risks associated with conducting business internationally.
The company is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability.

Future Outlook

The company expects to incur significant losses for the foreseeable future as it continues to conduct research and development, clinical testing, and regulatory compliance activities. The company expects its existing cash, which includes gross proceeds of approximately $6.6 million received in connection with the March 2025 Private Placement, will be sufficient to fund its operations into September 2025.

Management Comments

In March 2025, the company announced that its director Abizer Gaslightwala would be joining its management team as President and CEO effective April 21, 2025.
Mr. Gaslightwala brings a proven track record of successfully developing and commercializing oncology therapies as well as expertise in antibody-based therapies.

Industry Context

The document highlights the competitive landscape of the biotechnology and pharmaceutical industries, particularly in the oncology subsector. It notes the rapid technological evolution and the strong defense of intellectual property rights. The company faces competition from larger, better-funded companies, academic institutions, and research institutions. The document also mentions competition from companies developing new oncology therapeutics and the challenges of obtaining market acceptance and reimbursement for new products.

Comparison to Industry Standards

The document mentions approved Trop2-targeting ADCs such as Trodelvy and Datroway, indicating that AKTX-101 will compete with these existing therapies.
The document notes that over 90% of ADCs in late-stage clinical development utilize payloads from just two standard classes: microtubule inhibitors or DNA-damaging agents such as topoisomerase I inhibitors, highlighting Akari's differentiated approach with novel payloads.
The document compares the cytotoxicity of a Her2-PH1 ADC with that of Kadcyla, a Her2-targeting ADC commercially approved for use in the treatment of Her2-positive breast cancer, in in vitro gastric and breast cancer models.
The document compares AKTX-101 (drug antibody ratio (DAR) 4) to a currently approved Trop2-targeting ADC (with DAR 8) in in vitro preclinical studies.
The document compares AKTX-101 and the same currently approved ADC in an in vivo model against the same Trop2 high gastric carcinoma cell-line derived xenograft grown as tumors in mice.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President and CEO	Rachelle Jacques	Samir R. Patel, M.D. (Interim) / Abizer Gaslightwala (effective April 21, 2025)	May 1, 2024 (Interim) / April 21, 2025 (Permanent)	Resignation / Appointment

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Clawback Policy	The compensation committee adopted a formal clawback policy, which applies in the event the company is required to prepare an accounting restatement due to any material noncompliance with any financial reporting requirement under the U.S. federal securities laws.	November 27, 2023	The policy requires the company to recover from any of its current or former executive officers who receive incentive-based compensation after the effective date and during the three-year period preceding the date on which the company is required to prepare an accounting restatement, the excess of what would have been paid to such executive officer under the accounting restatement.

Legal Proceedings

In December 2024, the company received demand letters from two individuals formerly serving the company as consultants outlining claims relating to wrongful termination.
On November 21, 2024, Sabby Volatility Warrant Master Fund Ltd. (Sabby) filed a lawsuit against the company in New York state court for alleged breach of contract.

Related Party Transactions

The company leases office space for its U.K. headquarters in London from The Doctors Laboratory (TDL) and has incurred expenses of approximately $0.1 million plus VAT during each of the years ended December 31, 2024 and 2023, respectively.
Dr. Ray Prudo, the company's Director, is the non-Executive Chairman of the Board of Directors of TDL.
The company received certain laboratory testing services for its clinical trials provided by TDL, including certain administrative services, and incurred expenses of approximately $0.1 million during each of the years ended December 31, 2024 and 2023.
In November 2024, the company assumed an amount due to an entity in which the company's Chairman, Dr. Hoyoung Huh, is a director.

Stakeholder Impact

Shareholders may experience dilution from future equity offerings.
Employees may be affected by potential cost reductions or changes in strategic direction.
Patients may benefit from the development of new cancer therapies.
Suppliers and creditors may be impacted by the company's financial condition.

Next Steps

Advance AKTX-101 to IND and potential initiation of first-in-human (FIH) trial.
Progress AKTX-102, the discovery-stage ADC that utilizes PH1 against a novel cancer target.
Develop additional ADC programs that utilize the PH5 and PH6 payloads.
Leverage the ADC product candidates and payload library to partner with biopharmaceutical companies that desire to develop ADCs with novel payloads.
Out-license the legacy non-oncology assets.

Key Dates

Date	Description
October 7, 2004	Akari Therapeutics, Plc was originally established as a private limited company.
January 19, 2005	The company changed its name to Morria Biopharmaceuticals Limited.
February 3, 2005	The company completed a reverse merger with Morria Biopharmaceuticals Inc.
March 22, 2011	The company incorporated an Israeli subsidiary, Morria Biopharma Ltd.
June 25, 2013	The company changed its name to Celsus Therapeutics Plc.
October 13, 2013	Morria was renamed Celsus Therapeutics Inc.
January 3, 2014	The company changed the ratio of its ADSs to ordinary shares from one ADS representing two ordinary shares to a new ratio of one ADS representing ten ordinary shares.
September 18, 2015	The company completed an acquisition of all of the capital stock of Volution Immuno Pharmaceuticals SA.
September 21, 2015	The company's ADSs were listed on the Nasdaq Stock Market under the symbol AKTX.
September 17, 2015	The company changed the ratio of its ADSs to ordinary shares from one ADS representing ten ordinary shares to a new ratio of one ADS representing one hundred ordinary shares.
March 17, 2017	Peak Bio acquired the rights to PHP-303 and licensed associated know-how from Bayer Pharmaceuticals.
January 31, 2020	The UK ceased being a Member State of the EU.
January 1, 2021	The EU and the UK have concluded a trade and cooperation agreement (TCA), which was provisionally applicable.
May 1, 2021	The EU and the UK trade and cooperation agreement (TCA) has been formally applicable.
January 31, 2022	The EU Clinical Trials Regulation came into effect.
August 17, 2023	The company changed the ratio of its ADSs to ordinary shares from one ADS representing 100 ordinary shares to a new ratio of one ADS representing 2,000 ordinary shares.
November 7, 2024	Shareholders approved an increase to the number of authorized ordinary shares.
November 14, 2024	The company completed the business combination with Peak Bio, Inc.
December 16, 2024	Samir R. Patel, M.D., was appointed as President and Chief Executive Officer.
December 20, 2024	The FDA may only award a rare pediatric disease PRV if a sponsor has a rare pediatric disease designation for the drug or biologic before this date.
January 1, 2025	The medicines aspects of the Windsor Framework have applied since this date.
March 2, 2025	The company entered into a securities purchase agreement for a private placement.
March 14, 2025	The company entered into an Executive Offer of Employment Agreement with Mr. Abizer Gaslightwala.
April 21, 2025	Abizer Gaslightwala will serve as President and Chief Executive Officer, effective on or around this date.
September 30, 2026	The NDA or BLA for the product must be approved before this date to award a rare pediatric disease PRV.

Keywords

ADC, oncology, AKTX-101, clinical trials, financial risks, material weaknesses, internal control, net operating loss, capital, merger, biotechnology, pharmaceuticals, Trop2, payloads, nomacopan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.